Effects of Rituximab on JAK-STAT and NF-kappa B signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia
Makaleler > Tam Makale · 2019
Yazarlar: Aysegul Dalmlzrak, Nur SELVİ GÜNEL, Burçin KAYMAZ, Fahri ŞAHİN, Güray SAYDAM, Buket KOSOVA
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2019, cilt 44, ss 499-509
Özet
Objectives: Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-kappa B signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.